U.S. Home Infusion Therapy Devices Market Size, Share & Forecast 2026–2032

ID: MR-11259 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Home Infusion Therapy Devices
  • ✓Market Size 2024: USD 1.9 billion
  • ✓Market Size 2032: USD 3.3 billion
  • ✓CAGR: 7.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Legacy Pump Fleets Persist: Home infusion pharmacies keep legacy B. Braun Infusomat and BD Alaris fleets in service because pharmacy-side software integration makes switching costly. Replacement cycles, not new patient volume, will determine vendor share through 2028.
FINDING 02
Subcutaneous Shift Overstated: The consensus holds that subcutaneous biologics will erase home IV pump demand, but IV immunoglobulin and infliximab biosimilars still require pumps at home. Medicare's Part B home infusion therapy benefit keeps intravenous volumes growing through pharmacy and nursing channels.
ANALYST RECOMMENDATION

Analyst Recommendation — Pursue Payer Contracts Early: Device makers should secure dispensing agreements with the top three commercial payers and Medicare Advantage plans in Texas and Florida before the 2026 plan year. Each contract locks pump standardization for three years and ties device adoption to reimbursement.

Home Infusion Devices in the United States: Market Overview

The United States accounts for the largest share of global home infusion activity, supported by a commercial payer base and a Medicare Part B benefit that pays for home-based intravenous care. Device demand here is concentrated in ambulatory electronic pumps, elastomeric pumps, and syringe drivers used by licensed home infusion pharmacies. Unlike markets where hospitals dispense most IV therapy, the U.S. model routes patients out of acute settings through specialty pharmacies, which reshapes device purchasing toward pharmacy fleets rather than hospital capital budgets.

Market value for devices reached roughly USD 1.9 billion in 2024, a segment that sits inside a broader home infusion services market several times larger. Growth is steady rather than explosive, with the device category expanding at about 7.2 percent annually as pharmacy operators replace aging fleets and add antibiotic and immunoglobulin programmes. The structure is fragmented at the pharmacy level, with national operators such as Option Care Health competing against thousands of regional providers, which keeps device purchasing price-sensitive and favours vendors with bundled service support.

Growth Drivers in U.S. Home Infusion Devices

Adults aged 65 and older number roughly 61 million, and Medicare beneficiaries drive most home infusion referrals for chronic conditions such as heart failure and primary immunodeficiency. The Consolidated Appropriations Act of 2021 created the Medicare Part B home infusion therapy benefit, effective January 2021, which compensates qualified providers for professional services delivered in the home. Pump demand follows this reimbursement pathway because external infusion pumps are covered under Medicare's durable medical equipment rules through LCD L33794.

Biologic and immunoglobulin therapy is the second driver. Hospitals and specialty pharmacies are moving IVIG for immunodeficiency and infliximab biosimilars into home settings, which requires ambulatory pumps with dose-accuracy alarms. Third, outpatient parenteral antibiotic therapy grows as hospitals discharge patients earlier under Medicare's diagnosis-related group payment model, shifting volumes toward elastomeric pumps that cost less than electronic units.

Market Restraints and Entry Barriers

Entry requires a state board of pharmacy license in every state of operation, plus accreditation from The Joint Commission or ACHC, a process that typically takes six to twelve months. USP General Chapter 797 governs sterile compounding and applies to any pharmacy preparing infusate, raising facility capital costs for operators. Device vendors also face downstream traceability obligations under the Drug Supply Chain Security Act, which adds data-handling costs for pharmacies that buy and dispense sterile products.

Incumbent pump platforms, notably BD Alaris and Baxter's Sigma Spectrum, hold installed bases across pharmacies and hospitals, and interoperability with pharmacy management software is the main switching barrier. Medicare pays pump rental under fixed durable medical equipment fee schedules, which compresses device margins for new entrants. Commercial payers frequently require pharmacies to use preferred vendors, so a new pump company must win a payer contract before any pharmacy will evaluate its hardware.

Market Opportunities in the United States

The nearest opportunity lies in connected pump platforms. Pharmacies want devices that log dose data directly to electronic health records and pharmacy management systems, and vendors offering standards-based interfaces gain preferred status with payers. Analyst estimates place annual pump replacement demand at roughly USD 420 million, with connectivity upgrades accounting for a growing share of that spend.

Sun Belt states, particularly Florida and Texas, combine fast-growing senior populations with thin pharmacy coverage, creating under-served catchment areas for new pharmacy fleets. A second opportunity sits in low-cost elastomeric pumps for outpatient antibiotic programmes, where a disposable device priced below USD 150 per unit fits bundled reimbursement economics. Vendors that pair these pumps with nursing-visit software can capture both device and service revenue.

Market at a Glance

MetricValue
Market Size 2024USD 1.9 billion
Market Size 2032USD 3.3 billion
Growth Rate (CAGR)7.2%
Most Critical Decision FactorPayer contract access and pump interoperability with pharmacy systems
Largest RegionSouth (Texas, Florida, and Southeast states)
Competitive StructureConcentrated device suppliers with fragmented pharmacy operators

Leading Market Participants

  • Becton, Dickinson and Company
  • Baxter International
  • ICU Medical
  • B. Braun Medical
  • Fresenius Kabi
  • InfuSystem Holdings
  • Option Care Health
  • KORU Medical Systems
  • Hospira (Pfizer)
  • Medline Industries

Regulatory and Policy Environment

The FDA regulates ambulatory infusion pumps as Class II devices under 21 CFR 880.5725 and requires 510(k) clearance before commercial sale. Section 524B of the Federal Food, Drug, and Cosmetic Act, added by the Consolidated Appropriations Act of 2023, requires cybersecurity documentation in premarket submissions for connected devices. Pharmacy-side compliance falls to state boards of pharmacy and USP Chapter 797, whose revised standards took effect in December 2023.

CMS sets Medicare home infusion therapy payments under the Part B benefit, with per-visit rates for professional services updated annually through the Physician Fee Schedule. Pump rental is paid under durable medical equipment rules, and CMS has proposed reinstating DMEPOS competitive bidding, with the next round expected to begin contracts in the late 2020s. Vendors should map their pump portfolios against these timelines to avoid pricing exposure during bid cycles.

Long-Term Outlook for U.S. Home Infusion Devices

By 2032 the device market is projected to reach USD 3.3 billion, with electronic pumps retaining majority share as connected platforms become the procurement standard. Consolidation among pharmacy operators will concentrate purchasing decisions in fewer national accounts, favouring suppliers with multi-state service contracts and nationwide technical support. Growth will track the senior population and the expansion of biologic IV therapies into home settings.

Competitive dynamics will shift as ICU Medical integrates the infusion portfolio acquired from Smiths Medical and as Baxter and BD defend installed bases through software upgrades. Subcutaneous alternatives will limit growth in certain therapy areas, but intravenous immunoglobulin and biosimilar infusions keep pump demand positive. Entrants that secure payer access before 2028 will hold durable positions in the market.

Frequently Asked Questions

The fastest route is securing a preferred-vendor contract with a national home infusion pharmacy operator, which then pulls pump adoption across its branch network. Companies should target Texas and Florida first, where payer contracting and senior population growth align.
Devices require FDA 510(k) clearance under 21 CFR 880.5725, including Section 524B cybersecurity documentation for connected models. Pharmacy customers need state pharmacy licensure and ideally Joint Commission or ACHC accreditation.
Medicare pays pump rental under durable medical equipment fee schedules, which caps the revenue available to pharmacies for device use. Vendors must price within those rental economics to win pharmacy adoption.
Subcutaneous products reduce pump demand in some therapy areas but do not replace intravenous immunoglobulin or infliximab biosimilar infusions. Pump volumes therefore remain positive through the forecast period.
The largest barrier is interoperability with incumbent pharmacy management software, which locks in existing fleets. New brands must offer standards-based integration to displace established platforms.

Market Segmentation

By Product Type
  • Ambulatory Electronic Infusion Pumps
  • Elastomeric Infusion Pumps
  • Syringe Drivers
  • Infusion Sets and Accessories
By End User
  • Home Infusion Pharmacies
  • Hospice Agencies
  • Skilled Nursing Facilities
  • Self-Administering Patients
By Therapy Area
  • Anti-infectives and OPAT
  • Immunoglobulins
  • Biologics
  • Parenteral Nutrition

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 United States Home Infusion Therapy Devices - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Ambulatory Electronic Infusion Pumps
4.2 Elastomeric Infusion Pumps
4.3 Syringe Drivers
4.4 Infusion Sets and Accessories
4.5 Others
Chapter 05 End User Insights
5.1 Home Infusion Pharmacies
5.2 Hospice Agencies
5.3 Skilled Nursing Facilities
5.4 Self-Administering Patients
5.5 Others
Chapter 06 Therapy Area Insights
6.1 Anti-infectives and OPAT
6.2 Immunoglobulins
6.3 Biologics
6.4 Parenteral Nutrition
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Becton, Dickinson and Company
7.2.2 Baxter International
7.2.3 ICU Medical
7.2.4 B. Braun Medical
7.2.5 Fresenius Kabi
7.2.6 InfuSystem Holdings
7.2.7 Option Care Health
7.2.8 KORU Medical Systems
7.2.9 Hospira (Pfizer)
7.2.10 Medline Industries
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.